Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients - Retrospective Study of Japanese Real-World Data Through Clinical Chart Review
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 26 Dec 2018 Planned End Date changed from 31 Jan 2019 to 31 Oct 2019.
- 26 Dec 2018 Planned primary completion date changed from 31 Jan 2019 to 31 Oct 2019.
- 24 Jul 2018 Planned End Date changed from 29 Jun 2018 to 31 Jan 2019.